Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin plus vancomycin versus cefazolin plus placebo for surgical antimicrobial prophylaxis
ACTRN12618000642280Phase 4Completed
- Sponsor
- Monash University
- Start
- Jan 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in surgical site infection (SSI) and Healthcare-associated infection (HAI) comparing Cefazolin + vancomycin with Cefazolin + placebo (2 arms). Primary endpoint: Primary composite surgical site infection endpoint. Started Jan 2019; status: completed.
02
Drugs
vancomycincefazolin
03
Conditions
surgical site infection (SSI)Healthcare-associated infection (HAI)
Beyond the preview
Go deeper on ACTRN12618000642280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000642280.